Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
arGEN X (GB:0QW0)
:0QW0
Holding GB:0QW0?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
1.64Last Year’s EPS
-1.55Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 25, 2018
|% Change Since: 24.32%
|Next Earnings Date:Aug 02, 2018
Earnings Call Sentiment|Positive
The earnings call presents a positive outlook with strong revenue growth, successful product launches, and international expansion. However, the discontinuation of MN development and increased operating expenses are notable challenges.Company Guidance
During the call, argenx provided guidance on its financial performance and strategic initiatives for the third quarter of 2024. The company reported total operating income of $589 million, with $573 million in product net sales, reflecting a 20% quarter-over-quarter growth and a 74% increase from the same period last year. The product revenue was distributed across regions, with $492 million from the U.S., $24 million from Japan, $46 million from the rest of the world, and $11 million for product supply to Zai Lab in China. Operating expenses increased by $40 million to $575 million, resulting in an operating profit of $14 million. After tax, the quarterly profit was $91 million, contributing to a year-to-date profit of $59 million. The cash balance at quarter-end was $3.4 billion, with a revised cash guidance for 2024. Additionally, argenx highlighted the strong initial reception of its VYVGART Hytrulo in CIDP, with more than 300 patients treated in the last quarter, and emphasized ongoing strategic initiatives, including further product development and market expansion efforts.Strong CIDP Launch Performance
The CIDP launch exceeded expectations with over 300 patients on VYVGART Hytrulo by the end of the quarter, achieving revenue similar to the first MG quarter. 85-90% of these patients switched from IVIg, indicating strong market acceptance.
Record Revenue Growth
Total operating income for Q3 2024 was $589 million, with product net sales of $573 million, representing 20% quarter-over-quarter growth and 74% growth compared to the prior year quarter.
VYVGART's Continued Success in MG
VYVGART continues to drive significant growth in MG, with new prescribers and patients, expanding its market presence. Over 60% of new patients are coming from oral treatments.
International Expansion
VYVGART is now available to over 80% of the gMG population in the EU, and regulatory reviews for CIDP are ongoing in China, Japan, and Europe with approvals expected in 2025.
Positive Financial Outlook
The company reported a quarterly profit after tax of $91 million and a cash balance of $3.4 billion, with unchanged SG&A and R&D spend guidance for 2024.
---
GB:0QW0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0QW0 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | €513.16 | €529.63 | +3.21% |
| Jul 25, 2024 | €435.19 | €450.99 | +3.63% |
| May 09, 2024 | €367.38 | €336.89 | -8.30% |
| Feb 29, 2024 | €375.90 | €343.20 | -8.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does arGEN X (GB:0QW0) report earnings?
arGEN X (GB:0QW0) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is arGEN X (GB:0QW0) earnings time?
arGEN X (GB:0QW0) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of arGEN X stock?
The P/E ratio of arGEN X is N/A.
What is GB:0QW0 EPS forecast?
GB:0QW0 EPS forecast for the fiscal quarter 2024 (Q4) is 1.64.
---